Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Herceptin is a monoclonal antibody used to treat patients suffering from metastatic (spread) breast cancer and gastric cancers. Hereceptin is used as part of chemotherapy regimen for adjuvant treatment of lymph-node positive, HER2/neu protein positive breast cancer. Herceptin is also known as trastuzumab and mainly administered intravenously in cancer patients, the dose of herceptin given to patients is evaluated on the basis of patients' disease history and other physiological factors such as height, weight, type of cancer or disease condition. The first dose of Herceptin is administered intravenously for over 90 minutes, and if it is tolerated in patients then the maintenance dose is administered for 30 minutes.

The global Herceptin biosimilar market size is estimated to be valued at US$ 1.3 billion in 2020 and is expected to exhibit a CAGR of 24.5 % over the forecast period (2020-2027).

Figure 1. Global Herceptin Biosimilar Market Value (US$ Bn), 2016-2017

Herceptin Biosimilar  | Coherent Market Insights

The increasing prevalence of cancers such as breast cancer in women across the globe is a major factor driving the growth of the global herceptin biosimilar market. According to the World Health Organization’s report published in 2019, approximately 627,000 women across the globe died from breast cancer and it accounted for around 15% of all cancer deaths among women in 2018.

Furthermore, the increasing prevalence of gastric cancers such as metastatic gastric cancer are the factors expected to drive the growth of the global herceptin biosimilar market. According to the US National Library of Medicine’s report published in 2018, gastric cancer is the fifth most common neoplasm in people and third most deadly cancer across the globe. According to the same source, gastric cancer accounted for around 783,000 death globally in 2018.

request-sample

Herceptin Biosimilar Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 1.3 Bn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 24.5 % 2027 Value Projection: US$ 5.8 Bn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of the Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Indication: Breast Cancer, Gastric Cancer, Others.
  • By Distribution Channel: Hospitals, Oncology Centers, Others.
Companies covered:

Amgen Inc., AryoGen Biopharma, Biocon Limited, Celltrion Inc., Pfizer Inc., Merck & Co., Inc., Accord Healthcare Ltd, Gedeon Richter Plc, Genor Biopharma Company Ltd, Mabion SA, Mylan N.V, Roche Holding AG and Samsungbioepis Co,.Ltd.

Growth Drivers:
  • Robust product pipeline, approval of new Herceptin biosimilar drugs by key companies
  • Strategic mergers and acquisitions by key players
  • The increasing incidence of breast cancers and gastric cancers
Restraints & Challenges:
  • Major side effects associated with Herceptin such as pulmonary toxicity and embryo-fetal toxicity.

Global Herceptin Biosimilar Market – Impact of Coronavirus (COVID-19)

Following the outbreak of COVID-19 in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of the coronavirus (COVID-19) has resulted in more than 38 million infected individuals worldwide as of 16th October 2020.

COVID-19 has affected each and every market around the world and has also impacted the global herceptin biosimilar market in the following ways: by directly affecting the production and demand; by creating disruptions in distribution channels; and by its financial impact on firms and financial markets. Supply chain and manufacturing activities in India, China, and the U.S. have been disrupted due to nationwide lockdowns. While countries such as Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs from one place to another.

Moreover, various key players operating in the global herceptin biosimilar market are estimated to witness a decline in sales of biosimilars due to the COVID-19 pandemic and lockdowns imposed by governments in countries such as India, China, U.S. For instance, in July 2020, Roche Holding AG, a leading manufacturing of oncology medicines, stated that Roche’s top three selling biosimilar, Avastin, Rituxan and Herceptin experienced drop in sales of nearly 39%, 33% and 46% respectively due to the COVID-19 pandemic. Moreover, Roche witnessed loss of US$ 2.3 billion in the first quarter of 2020.

Figure 2. Global Herceptin Biosimilar Market Share (%), by Region, 2020

Herceptin Biosimilar  | Coherent Market Insights

Among regions, North America is expected to witness significant growth in the global herceptin biosimilar market during forecast period, as companies focusing on obtaining approvals and launching products for treatment of cancers such breast and gastric cancer. For instance, in 2019, Amgen Inc. and Allergan plc. collaboratively launched KANJINTI (trastuzumab) for treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. KANJINTI received approval from the U.S. Food Drug and Administration and can be used for treatment of breast cancer and gastric cancer throughout the U.S.

Key Players

Major players operating in the global herceptin biosimilar market include Amgen Inc., AryoGen Biopharma, Biocon Limited, Celltrion Inc., Pfizer Inc., Merck & Co., Inc., Accord Healthcare Ltd, Gedeon Richter Plc, Genor Biopharma Company Ltd, Mabion SA, Mylan N.V, Roche Holding AG and Samsungbioepis Co,.Ltd.

Trastuzumab, sold under the brand Herceptin, is a monoclonal antibody used for the treatment of breast cancer and gastric cancer. Herceptin is mainly used to treat patients suffering from cancer and diagnosed with HER2 receptor positive. Herceptin mechanism of action is binding itself to HER2 receptors on the surface of breast cancer cells and blocking them from receiving growth signals and thus decreasing the mutation of cells. Herceptin acts as an immune targeted therapy for breast cancer patients.

Market Dynamics

Product approvals and launches are the factors driving the growth of the global herceptin biosimilar market. For instance, in February 2020, Pfizer Inc., a biotechnology and pharmaceutical company in the U.S., launched the trastuzumab biosimilar, Trazimera, for treatment of human epidermal growth receptor causing breast cancer and metastatic gastric cancer.

Key features of the study:

  • This report provides in-depth analysis of the global herceptin biosimilar market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global Herceptin biosimilar market based on the following parameters – company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study are Amgen Inc., AryoGen Biopharma, Biocon Limited, Celltrion Inc., Pfizer Inc., Merck & Co., Inc., Accord Healthcare Ltd, Gedeon Richter Plc, Genor Biopharma Company Ltd, Mabion SA, Mylan N.V, Roche Holding AG and Samsungbioepis Co,.Ltd
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global herceptin biosimilar market report caters to various stakeholders in this industry including investors, suppliers, device manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global herceptin biosimilar market.

Detailed Segmentation:

  • Global Herceptin Biosimilar Market, By Indication:
    • Breast Cancer
    • Gastric Cancer
    • Others
  • Global Herceptin Biosimilar Market, By Distribution Channel :
    • Hospitals
    • Oncology Centers
    • Others
  • Global Herceptin Biosimilar Market, By Region:
    • North America
      • By Indication:
        • Breast Cancer
        • Gastric Cancer
        • Others
      • By Distribution Channel :
        • Hospital
        • Oncology Centers  
        • Others
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Indication:
        • Breast Cancer
        • Gastric Cancer
        • Others
      • By Distribution Channel :
        • Hospital
        • Oncology Centers 
        • Others
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Indication:
        • Breast Cancer
        • Gastric Cancer
        • Others
      • By Distribution Channel :
        • Hospital
        • Oncology Centers 
        • Others
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Indication:
        • Breast Cancer
        • Gastric Cancer
        • Others
      • By Distribution Channel :
        • Hospital
        • Oncology Centers 
        • Others
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Indication:
        • Breast Cancer
        • Gastric Cancer
        • Others
      • By Distribution Channel :
        • Hospital
        • Oncology Centers 
        • Others
      • By Country/Region:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Indication:
        • Breast Cancer
        • Gastric Cancer
        • Others
      • By Distribution Channel :
        • Hospital
        • Oncology Centers 
        • Others
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Amgen Inc. *
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • AryoGen Biopharma
    • Biocon Limited
    • Celltrion Inc.
    • Pfizer Inc.
    • Merck & Co., Inc.
    • Accord Healthcare Ltd.
    • Gedeon Richter Plc.
    • Genor Biopharma Company Ltd
    • Mabion SA
    • Mylan N.V.
    • Roche Holding AG
    • Samsungbioepis Co,.Ltd

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Indication
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
      • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Impact Analysis
    • Market Opportunities
    • Regulatory Scenario
    • Recent Product Approval/ Launch
    • Key Development
    • PEST Analysis
    • Epidemiology
    • Mergers and Acquisitions
    • Value Chain Analysis
  4. Global Herceptin Biosimilar Market, Impact of COVID-19 Pandemic
    • Post COVID-19 Impact
    • Demand and Supply Chain Analysis
    • Government Initiative
  5. Global Herceptin Biosimilar Market, By Indication, 2016-2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
        • Breast Cancer
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Gastric Cancer
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Others
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  6. Global Herceptin Biosimilar Market, By Distribution Channel, 2016–2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
        • Hospitals  
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Oncology Centers
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Others
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  7. Global Herceptin Biosimilar Market, By Region, 2016–2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Countries, 2017–2027
    • North America
      • Introduction
      • Market Size and Forecast, By Indication , 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, By Indication , 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, By Indication , 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • Germany
        • U.K.
        • France       
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, By Indication , 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, By Indication , 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, By Indication , 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Company Profiles
      • Amgen Inc.
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • AryoGen Biopharma
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Biocon Limited
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Celltrion Inc.
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pfizer Inc.
        •  Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Accord Healthcare Ltd.
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Gedeon Richter Plc.
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Genor Biopharma Company Ltd
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Mabion SA
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Mylan N.V.
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
        • Market Strategies
      • Roche Holding AG
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
        • Market Strategies
      • Samsungbioepis Co,.Ltd
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
        • Market Strategies

 *Browse 33 market data tables and 32 figures on "Herceptin Biosimilar Market– Global forecast to 2027”.

Frequently Asked Questions

The global herceptin biosimilar market size is estimated to be valued at US$ 1.3 billion in 2020 and is expected to exhibit a CAGR of 24.5 % between 2020 and 2027.
Robust product pipeline, approval of new Herceptin biosimilar drugs by key companies, strategic mergers and acquisitions by key players, and the increasing incidence of cancers such as breast cancer and gastric cancer are the factors driving the global herceptin biosimilar market growth.
Breast cancer segment is estimated to hold major market share in the global herceptin biosimilar market owing to the increasing prevalence of breast cancer in women.
North America is estimated to generate the highest revenue share in 2020 in the global herceptin biosimilar market.
Herceptin is administered intravenously and can lead to serious side effects such as pulmonary toxicity and embryo-fetal toxicity which is a key factor hampering growth of the market.
Major players operating in the global herceptin biosimilar market include Amgen Inc., AryoGen Biopharma, Biocon Limited, Celltrion Inc., Pfizer Inc., Merck & Co., Inc., Accord Healthcare Ltd, Gedeon Richter Plc, Genor Biopharma Company Ltd, Mabion SA, Mylan N.V, Roche Holding AG and Samsungbioepis Co,.Ltd.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner